Business Description
Coherus Oncology Inc
NAICS : 541714
SIC : 2834
ISIN : US19249H1032
Total Employee Number:
144Description
Coherus Oncology Inc. is a commercial-stage biopharmaceutical company focused on oncology. Its lead product is LOQTORZI (toripalimab-tpzi), a next-generation PD-1 inhibitor approved for nasopharyngeal carcinoma, which the company markets in the United States following a licensing arrangement with Shanghai Junshi Biosciences. Coherus also markets UDENYCA, a pegfilgrastim biosimilar used to prevent chemotherapy-induced neutropenia, and has divested or de-emphasized several non-oncology assets, including its ophthalmology franchise. The company's clinical pipeline includes mid-stage candidates targeting liver, lung, and head and neck cancers, developed through internal research and partnerships. Revenue comes primarily from product sales of LOQTORZI and UDENYCA in the U.S. market, supplemented by licensing and collaboration arrangements. Coherus is headquartered in Redwood City, California, and sells to oncology clinics, hospitals, and specialty distributors across the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.69 | |||||
Equity-to-Asset | 0.32 | |||||
Debt-to-Equity | 0.64 | |||||
Debt-to-EBITDA | -0.26 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -11.36 | |||||
Beneish M-Score | -0.95 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -49 | |||||
3-Year EBITDA Growth Rate | 23.9 | |||||
3-Year EPS without NRI Growth Rate | 23.4 | |||||
3-Year FCF Growth Rate | 27.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 23.87 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 59.37 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 56.32 | |||||
9-Day RSI | 52.63 | |||||
14-Day RSI | 51.13 | |||||
3-1 Month Momentum % | -14.38 | |||||
6-1 Month Momentum % | -28.77 | |||||
12-1 Month Momentum % | -8.89 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.56 | |||||
Quick Ratio | 3.18 | |||||
Cash Ratio | 2.8 | |||||
Days Inventory | 132.19 | |||||
Days Sales Outstanding | 97.62 | |||||
Days Payable | 447.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.4 | |||||
Shareholder Yield % | 57.47 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 68.94 | |||||
Operating Margin % | -311.56 | |||||
Net Margin % | -259.41 | |||||
EBITDA Margin % | -293.15 | |||||
FCF Margin % | -362.32 | |||||
OCF Margin % | -362.32 | |||||
ROE % | -161.9 | |||||
ROA % | -39.52 | |||||
ROIC % | -225.76 | |||||
3-Year ROIIC % | -70.22 | |||||
ROC (Joel Greenblatt) % | -11109.22 | |||||
ROCE % | -105.69 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.31 | |||||
PB Ratio | 3.27 | |||||
Price-to-Tangible-Book | 12.97 | |||||
EV-to-EBIT | -0.94 | |||||
EV-to-Forward-EBIT | 4.57 | |||||
EV-to-EBITDA | -0.96 | |||||
EV-to-Forward-EBITDA | 4.51 | |||||
EV-to-Revenue | 2.79 | |||||
EV-to-Forward-Revenue | 1.28 | |||||
EV-to-FCF | -0.76 | |||||
Price-to-GF-Value | 1.31 | |||||
| Price-to-Net-Current-Asset-Value | 58.35 | |||||
Earnings Yield (Greenblatt) % | -106.87 | |||||
FCF Yield % | -89.16 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 43.681 | ||
| EPS (TTM) (€) | -0.875 | ||
| Beta | 2.4889 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.26 | ||
| Volatility % | 93.23 | ||
| 14-Day RSI | 51.13 | ||
| 14-Day ATR (€) | 0.045605 | ||
| 20-Day SMA (€) | 1.16335 | ||
| 12-1 Month Momentum % | -8.89 | ||
| 52-Week Range (€) | 0.9432 - 2.188 | ||
| Shares Outstanding (Mil) | 154.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus Oncology Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-03-09 16:30 | In 169 days | ||
| Annual report for 2026 | 2027-03-09 | In 168 days | ||
| Fourth quarter earnings results for 2026 | 2027-03-09 | In 168 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 17:00 | In 46 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 45 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-05 17:00 | 1.24 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-05 | 1.24 (+0.00%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 09:55 | 1.29 (+0.00%) | ||
| General meeting for 2026 | 2026-05-27 13:30 | 1.38 (+0.00%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-26 15:00 | 1.38 (+0.00%) |
Show
Entries
Coherus Oncology Inc Frequently Asked Questions
What is Coherus Oncology Inc(FRA:8C5)'s stock price today?
The current price of FRA:8C5 is €1.17. The 52 week high of FRA:8C5 is €2.19 and 52 week low is €0.94.
When is next earnings date of Coherus Oncology Inc(FRA:8C5)?
The next earnings date of Coherus Oncology Inc(FRA:8C5) is 2026-11-06 Est..
Does Coherus Oncology Inc(FRA:8C5) pay dividends? If so, how much?
Coherus Oncology Inc(FRA:8C5) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers